from the April preliminary results....In total, 20 out of 24...

from the April preliminary results....

In total, 20 out of 24 patients were evaluable for efficacy, with 15 patients at Stage IV (the most advanced stage of ovarian cancer), and the remainder were Stage III.

Preliminary analysis shows one complete response (no measurable disease after treatment) and two partial responses (tumour shrunk is size by at least 30%).

This means an overall response rate of 15% (three out of 20 patients) which compares favourably to a figure of 10% for historical controls.

So the patients were at a very late stage.

Hopefully a large Pharma will be interested. Very soon would be nice!